- Published at
- by manilatimes.net
positive
positive
PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection
Largest Series A financing round in Asia's diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific's breakthrough diagnostic technology and growth vision. Investment to accelerate R&D and commercialization of cutting-edge early disease detection technology for multiple cancers, women's health issues, and infectious diseases. HONG KONG, May 20, 2025 /PRNewswire/ -- PHASE Scientific International Limited ('PHASE Scientific'), a pioneering biotechnology company revolutionizing early disease detection through proprietary urine-based diagnostics, today announced the successful completion of a US$34 million Series A funding round. This represents the largest Series A raise in Asia's diagnostic technology sector since 2019, reflecting robust investor conviction in PHASE Scientific's innovative PHASIFY™ technology and ambitious growth strategy. The funding round is led by a private equity fund managed by Value Partners Group (HKEX: 0806), one of Asia's largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers.